Press Release

Tarlige® Tablets Approved in Japan for Treatment of Patients with Neuropathic Pain

Tokyo, Japan - (March 28, 2022) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that it has obtained approval in Japan to change the indication of the analgesic “Tarlige® Tablets” (mirogabalin besilate) from “peripheral neuropathic pain” to “neuropathic pain.”

Neuropathic pain is pain caused by lesions or diseases of the somatosensory nervous system and is classified into peripheral neuropathic pain and central neuropathic pain (CNP), according to the anatomical location of the nerve damage site that causes the pain. CNP is pain that arises from central nerve injury or impairment such as spinal cord injury and central post-stroke pain.

In May 2021, Daiichi Sankyo submitted a supplemental new drug application (sNDA) for Tarlige® Tablets based on results from a phase 3 trial in patients with CNP.

By delivering a new therapeutic option for CNP, Daiichi Sankyo hopes to contribute to healthcare of patients.

About Tarlige®

Tarlige® is an analgesic proprietarily discovered by Daiichi Sankyo that works by inhibiting excessive release of pain-related neurotransmitters in presynaptic nerve terminal. Tarlige® was approved for the indication of “peripheral neuropathic pain” in Japan in January 2019 and was launched in April of the same year.

Brief description of Tarlige® Tablets

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Tarlige® Tablets 2.5 mg, 5 mg, 10 mg, and 15 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name (JAN)</td>
<td>Mirogabalin besilate</td>
</tr>
<tr>
<td>Indication</td>
<td>Neuropathic pain</td>
</tr>
<tr>
<td>Date of Partial Change Approval</td>
<td>March 28, 2022</td>
</tr>
<tr>
<td>Manufacturing and Marketing</td>
<td>Daiichi Sankyo Company, Limited</td>
</tr>
</tbody>
</table>
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp